Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Accumulated Expenses: 2015-2021

Historic Accumulated Expenses for Assembly Biosciences (ASMB) over the last 7 years, with Sep 2021 value amounting to $3.7 million.

  • Assembly Biosciences' Accumulated Expenses fell 15.88% to $3.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $3.7 million, marking a year-over-year decrease of 15.88%. This contributed to the annual value of $4.4 million for FY2020, which is 16.34% down from last year.
  • As of Q3 2021, Assembly Biosciences' Accumulated Expenses stood at $3.7 million, which was up 1.85% from $3.7 million recorded in Q2 2021.
  • Assembly Biosciences' Accumulated Expenses' 5-year high stood at $10.1 million during Q1 2019, with a 5-year trough of $3.7 million in Q2 2021.
  • Over the past 3 years, Assembly Biosciences' median Accumulated Expenses value was $4.5 million (recorded in 2020), while the average stood at $5.6 million.
  • Per our database at Business Quant, Assembly Biosciences' Accumulated Expenses surged by 222.84% in 2017 and then plummeted by 54.31% in 2020.
  • Assembly Biosciences' Accumulated Expenses (Quarterly) stood at $6.1 million in 2017, then fell by 18.37% to $5.0 million in 2018, then grew by 6.01% to $5.3 million in 2019, then dropped by 16.34% to $4.4 million in 2020, then dropped by 15.88% to $3.7 million in 2021.
  • Its Accumulated Expenses stands at $3.7 million for Q3 2021, versus $3.7 million for Q2 2021 and $4.3 million for Q1 2021.